Mumbai-based AI healthcare startup Qure.ai has secured $65 million in a Series D funding round led by Lightspeed and 360 ONE Asset, with participation from prominent investors including Merck Global Health Innovation Fund, Novo Holdings, and Kae Capital. Founded in 2016, Qure.ai specializes in using artificial intelligence to analyze medical images like X-rays and CT scans, providing fast and accurate diagnostic support to healthcare providers globally.
The newly raised capital will fuel Qure.ai’s aggressive expansion plans, particularly in the U.S. market, as well as investment in foundational AI models and potential acquisitions of med-tech companies. The startup’s innovative technology is designed to identify early-stage diseases, such as lung cancer and stroke, and is currently deployed in over 90 countries across 3,000 sites. By integrating its AI systems into existing healthcare infrastructures, Qure.ai aims to alleviate bottlenecks, improve diagnostic accuracy, and make healthcare more accessible—especially in resource-constrained environments.
CEO Prashant Warier highlighted that Qure.ai’s solutions are already in use across a diverse range of facilities, from NHS hospitals in the UK to rural health initiatives in developing countries. By comparing new medical images with billions of clinical data points, the AI technology supports doctors by providing insights that may be missed by the human eye, enabling quicker and more accurate diagnoses.
This round of funding builds on Qure.ai’s previous success, including a $40 million raise in 2022. With this momentum, the startup is well-positioned to continue its mission to bring cutting-edge healthcare technology to a billion patients worldwide.
Credit: This article has been taken from Indian Startup News
Key Highlights:
- Qure.ai raised $65 million in Series D funding to expand into the U.S. and other markets.
- The round was led by Lightspeed and 360 ONE Asset, with Merck Global Health Innovation Fund and Novo Holdings participating.
- Qure.ai’s AI solutions are deployed in over 90 countries across 3,000 sites, providing faster and more accurate medical diagnoses.
- The company aims to improve access to healthcare in resource-constrained environments through AI-driven diagnostics.
